Date: 2014-09-16
Type of information: Nomination
Compound: chief executive officer
Company: Dimension Therapeutics (USA - MA)
Therapeutic area: Rare diseases
Type agreement: nomination
Action mechanism:
Disease:
Details:
- • On September 16, 2014, Dimension Therapeutics, a gene therapy company focused on developing novel treatments for rare diseases, announced that Annalisa Jenkins, MBBS, MRCP has been appointed as chief executive officer. Dr. Jenkins succeeds interim chief executive officer, Thomas Beck, M.D. Dr. Jenkins brings to Dimension nearly 20 years of experience in building and leading teams that advanced programs from scientific research through clinical development, regulatory approval and into healthcare systems globally. Prior to joining Dimension, Dr. Jenkins served as executive vice president, head of global research and development for Merck Serono, where she also led global medical affairs and quality. Prior to Merck Serono, Dr. Jenkins held several roles of increasing responsibility at BMS. During her tenure at BMS, she made significant contributions to the progression and approval of a number of key pipeline programs, including Eliquis®, Orencia®, Sprycel®, Yervoy®, Erbitux®, Abilify® and Plavix®. She also played a key role in the implementation of BMS’s business development strategy, including the acquisition of Medarex and major partnerships with Pfizer and Astra Zeneca.
- Dr. Jenkins currently serves as chair of the board of Transcelerate Biopharma Inc. and as a member of the board of directors of Biothera and Prosensa. She also serves on the board of Women in Bio, the UK Task Force for the Center for Talent Innovation and The Concert Artists Guild of New York. She was named both the Healthcare Businesswomen’s Association and IIR Partnerships’ Woman of the Year in 2014. Dr. Jenkins graduated with a degree in medicine from St. Bartholomew’s Hospital in the University of London and subsequently trained in cardiovascular medicine in the UK National Health Service. Earlier in her career, Dr. Jenkins served as a medical officer in the British Royal Navy during the Gulf Conflict in 1991 and subsequently rose to the rank of surgeon lieutenant commander.
Financial terms:
Latest news:
Is general: Yes
